TG Therapeutics(NASDAQ) TGTX

TG Therapeutics creates medicines for people with autoimmune diseases and certain cancers. Their main product helps adults manage a common nervous system disorder called multiple sclerosis. The company finds and develops new ways to stop the body from attacking itself.

The Product Portfolio

• BRIUMVI: An intravenous infusion for adults with relapsing forms of multiple sclerosis; administered as a one-hour treatment every 24 weeks after initial doses.
• Subcutaneous Ublituximab: An under-the-skin injection version of the company’s main drug currently undergoing late-stage clinical testing.
• Azer-cel: A cell therapy using modified donor cells to treat progressive forms of multiple sclerosis; currently in early clinical trials.
• Drug Pipeline: Several experimental treatments for B-cell diseases, which are conditions caused by malfunctioning white blood cells.

Strategic Moves and Partnerships

• Partnered with Neuraxpharm in August 2023 to sell BRIUMVI in Europe and other regions outside the United States.
• Acquired a global license from Precision BioSciences in January 2024 to develop azer-cel for autoimmune diseases.
• Collaborated with Samsung Biologics and FUJIFILM Diosynth Biotechnologies to manufacture their drug supplies.
• Launched a public awareness platform called Next In MS in early 2025 to foster dialogue about living with multiple sclerosis.

A Specialized Development Network

The company operates as a fully integrated biotechnology firm with a team focused on B-cell mediated diseases. They use a specific licensing strategy to acquire drug candidates that have already shown activity in human clinical trials.

Financial Results and Growth

• Total revenue reached $192.6 million in Q4 2025, a 78% increase from $108.2 million in Q4 2024.
• Operating income rose to $50.5 million in Q4 2025, up 68.6% from $29.9 million in the previous year.
• Free cash flow turned positive at $19.6 million in Q4 2025 compared to a loss of $25.7 million in Q4 2024.
• Net income was $23 million in Q4 2025, representing a slight 1.3% decrease from $23.3 million in Q4 2024.

Evolution and Future Focus

TG Therapeutics has transitioned from a research-focused firm to a commercial-stage company with growing international reach. By expanding its multiple sclerosis treatments and cell therapy research, the company continues to diversify its approach to autoimmune care.